RecruitingPhase 2NCT07005180

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)

Sponsor

Hillhurst Biopharmaceuticals, Inc.

Enrollment

36 participants

Start Date

Jun 30, 2026

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

Eligibility

Min Age: 40 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HBI-002 and a drug called Vehicle (placebo) for people with parkinson disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 40 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHBI-002

Oral liquid containing carbon monoxide

DRUGVehicle (placebo)

Vehicle control (placebo)

Locations(8)

The Parkinson's & Movement Disorder Institute

Fountain Valley, California, United States

University of Florida

Gainesville, Florida, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Michigan State University

East Lansing, Michigan, United States

Quest Research Institute

Farmington Hills, Michigan, United States

Weill Cornell Medical College

New York, New York, United States

Inland Northwest Research

Spokane, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07005180

Related Trials

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

NCT070563611 location

Neurodegenerative Diseases Registry

NCT04472130

Visuomotor Control in Parkinson Disease

NCT069189381 location

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

NCT0697626815 locations

Does Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease?

NCT07802509